Symbiotec Pharmalab targets 20-25% revenue growth in FY27
The pharmaceutical company expects large commercial milestones in the second half to offset first-quarter margin drags, while a new ₹400 crore biotech vertical is set to begin generating revenue by the fourth quarter.
\